Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
475.91
-2.67 (-0.56%)
At close: Oct 28, 2025, 4:00 PM EDT
476.02
+0.11 (0.02%)
After-hours: Oct 28, 2025, 6:45 PM EDT
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
The 26 analysts that cover Alnylam Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $466.46, which forecasts a -1.99% decrease in the stock price over the next year. The lowest target is $298 and the highest is $583.
Price Target: $466.46 (-1.99%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 13 | 13 | 14 | 13 |
| Buy | 9 | 8 | 9 | 10 | 11 | 11 |
| Hold | 3 | 3 | 3 | 4 | 4 | 3 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 24 | 23 | 26 | 27 | 29 | 27 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $459 → $535 | Strong Buy | Maintains | $459 → $535 | +12.42% | Oct 17, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $475 → $473 | Buy | Maintains | $475 → $473 | -0.61% | Oct 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $570 | Strong Buy | Reiterates | $570 | +19.77% | Oct 10, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $405 → $475 | Hold | Maintains | $405 → $475 | -0.19% | Oct 6, 2025 |
| Stifel | Stifel | Strong Buy Maintains $441 → $495 | Strong Buy | Maintains | $441 → $495 | +4.01% | Oct 6, 2025 |
Financial Forecast
Revenue This Year
3.60B
from 2.25B
Increased by 60.04%
Revenue Next Year
5.06B
from 3.60B
Increased by 40.69%
EPS This Year
1.39
from -2.18
EPS Next Year
5.76
from 1.39
Increased by 313.17%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.0B | 8.0B | |||
| Avg | 3.6B | 5.1B | |||
| Low | 3.2B | 4.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 79.3% | 122.1% | |||
| Avg | 60.0% | 40.7% | |||
| Low | 44.5% | 13.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.86 | 13.91 | |||
| Avg | 1.39 | 5.76 | |||
| Low | -1.11 | 0.12 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 898.5% | |||
| Avg | - | 313.2% | |||
| Low | - | -91.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.